A recent study has also proved that EZH2 inhibition could relieve hyperuricemia-induced renal injury and fibrosis, suggesting its promise as a potential strategy for the treatment of hyperuricemia-induced CKD [39]. Here, EZH2 is linked to chronic kidney disease.